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What is already known about the topic?
 Chelation therapy is a costly therapeutic option for the
treatment of coronary artery disease.
 There is no current empirical evidence for its use.
R T I C L E I N F O
icle history:
ceived 6 October 2011
ceived in revised form 19 March 2012
cepted 30 March 2012
ywords:
ronary artery disease
elation therapy
cision-making
scriptive decision-modeling
A B S T R A C T
Background: A considerable number of patients receive chelation therapy to treat their
coronary artery disease. However, there is no current empirical evidence to support its use.
Aim: To better understand patient’s decision-making processes regarding the use of
chelation therapy as a treatment for coronary artery disease.
Methods: Based on qualitative interviews with 32 coronary artery disease patients, a
taxonomy of decision-related issues, hierarchical decision-model, and survey based on the
model were developed. The model was then pilot tested with another group of 30 patients
and revised accordingly. The ﬁnal model was tested with another group of 167 patients (27
current users, 72 previous users, and 68 never users of chelation therapy). The primary
examination of the model was to determine the degree to which it successfully identiﬁed
people who fell within each behavioral group. This was done by dividing the total number
of successes by the total number of cases on all paths (or questions in the questionnaire).
Results: The most important elements in the decision to use or not use chelation therapy
were: previous experience with or learning about chelation therapy, openness to
alternative treatments, satisfaction with current level of (traditional) care, physician
opinion regarding chelation therapy, costs associated with chelation therapy, perceived
access to chelation therapy provider, current state of health (good or bad), and wanting to
do ‘all one can’ for heart health. When tested, the ability of the model to predict the
appropriate outcome was nearly 93%. The most salient junctures in the model that led
participants to different behavioral outcomes were: considering using non-traditional
treatments; perceptions regarding potential risks and beneﬁts; cost; and believing that
using chelation therapy was ‘doing all that they can’ to help their heart health.
Conclusions: Descriptive decision-modeling is a useful method to depict cardiac patients’
decision-making concerning the use of chelation therapy. It can also assist healthcare
providers and policy makers in directing interventions and policy aimed at enhancing the
use of evidence-based therapies for cardiac patients.
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patients opt to pay for this unproven treatment.
What this paper adds
 ‘Proof of effectiveness’ of the treatment is not related to
patients’ decision to use chelation therapy.
 Patients often use chelation therapy because they are
dissatisﬁed with current relationships and processes
associated with traditional care or they have no other
treatment options.
 Descriptive decision modeling is an effective way of
exploring patients’ healthcare choices.
. Introduction
.1. Chelation therapy
Ethylenediamine-tetraacetic acid (EDTA), the most
ommonly used chelation agent, extracts minerals from
e circulation when given intravenously. It is used to treat
xcesses (e.g., poisoning) of minerals such as lead and
ercury in animal models and in humans. Calcium is
nother mineral (a divalent cation) for which EDTA has an
fﬁnity. Chelation therapy advocates propose that EDTA
hould extract calcium from coronary artery lesions and
ereby improve coronary artery circulation (Holden, 2002;
amas and Ackerman, 2000; Shen and Hirschtick, 2004).
Despite the pathophysiologic reasons which suggest that
T may improve CAD, the evidence regarding its effective-
ess (based predominantly observational studies (Ernst,
997, 2000; Grier and Myers, 1993) and few clinical trials
nderson et al., 2003; Knudtson et al., 2002)) is equivocal.
hough the National Heart, Lung, and Blood Institute and the
ational Center for Complementary and Alternative Med-
ine (National Institutes of Health, United States) have co-
ponsored a major clinical trial, designed to test the efﬁcacy
nd safety of CT in CAD patients; results are not expected for
ome time. Thus, the Canadian Cardiovascular Society
997) and the American Heart Association currently
aution against its use. The American Heart Association
dditionally warns that using CT may deprive patients of the
stablished beneﬁts of many other valuable CAD treatments.
A considerable number of coronary artery disease (CAD)
atients receive chelation therapy, though there is no
urrent empirical evidence to support its use (Knudtson
t al., 2002; Seely et al., 2005; Villarruz et al., 2004).
merican estimates have suggested that upwards of
0,000 CAD patients receive chelation therapy annually
arns et al., 2002). Traditional evidence-based therapies
re widely available for CAD patients; particularly in
ublically funded healthcare systems (such as Canada’s).
onetheless, evidence-based therapies are under-used and
atients seek alternatives. Chelation therapy has been
alled ‘one of the most aggressive and intensive of
lternative therapies’ for CAD (Lamas and Hussein, 2006).
.2. The patients’ perspective
Patients may have their own perspectives regarding
eir health and treatments for illness, which may or may
not be in keeping with scientiﬁc evidence (Kleinman,
1995). In a survey of 96 CT users, Quan et al. (2007) found
21% believed that it could cure their heart disease, 44%
believed that it could relieve their symptoms, and 58%
believed that it could increase their quality of life. Only 17%
believed that it could have some side effects. Participants
reported that they used CT to ‘bring their health to the
highest possible level’ (61%); ‘to seek every option possible’
to treat their heart disease (58%); and ‘to avoid heart
surgery’ (56%).
Medical anthropologist Kleinman (1995) contended
that healthcare providers must understand the beliefs and
choices of the patient to effectively provide care. People’s
behavior is linked to their appraisal of situations, or their
explanatory models. If healthcare providers are cognizant
of basis for patient’s health behaviors (e.g., their explana-
tory or decision models), they can more effectively assist
patients to make healthcare choices.
1.3. Decision models
Generally, decision-models can be either normative or
descriptive. Normative decision models are oriented to
determining how people should make choices to reach an
optimal decision, whereas descriptive decision models are
oriented to describing on a group level, the reasoning
process that lead people to a particular decision (Garro,
1998; Ogden, 2003; Tversky and Kahneman, 1981).
Descriptive decision-modeling, such as that described by
Gladwin (1989), is oriented toward determining how
individuals actually make choices and arrive at their own
decisions (Garro, 1998; Gladwin, 1989). Decision-making
is viewed as a series of contextually bound choices.
Gladwin (1989) argues that this modeling mechanism
better reﬂects the actual way that people make decisions.
‘‘No one assigns weights to several variables (at a time) and
then adds them up to determine which of several
outcomes is better; people compare alternatives one
dimension at a time.’’(p. 11)
Ethnographic decision-modeling is a descriptive deci-
sion-modeling method used primarily by anthropologists
(Bauer and Wright, 1996; Gladwin et al., 2001; Hurwicz,
1995), but also by health disciplines (Beck, 2005;
Montbriand, 1995a; Oh and Park, 2004) to describe and
predict group behavior in situations where individuals are
making the decision. It is an excellent tool for better-
understanding how patients make choices about their
health care. Thus, using ethnographic decision-modeling,
we aimed to better understand, from the patient’s
perspective, the factors that inﬂuence their decision-
making to use or not use chelation therapy as an
alternative or adjunctive therapy for CAD.
2. Methods
As described by Gladwin (1989), we used a three-
staged, multi-methods approach to develop and test an
ethnographic decision-model that reﬂects the decision-
making process of CAD patients regarding their use (or
not) of chelation therapy. This entailed: (A) decision-tree
model building (qualitative-ethnographic interviews),
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) decision-tree model testing (survey methods).
. Sample pool (Stages A, B, and C)
Participants for this study, persons diagnosed with
ronary artery disease (CAD), were identiﬁed and
cruited through the Alberta Provincial Program for
tcome Assessment in Coronary Heart Disease
PPROACH) database. APPROACH, conceived and initiated
 Alberta, Canada is aimed at gathering baseline clinical
ta, as well as socio-demographic, short- and long-term
tcomes data for all patients presenting for cardiac
theterization (Ghali and Knudtson, 2000). One year
llowing entry into the APPROACH database, patients are
ntacted to participate in a cross sectional survey and to
nsent to be contacted for further study. From January
96 until July 2007, the survey included a question
garding chelation therapy use (current, previous, or
ver user (Quan et al., 2001, 2007).
Following necessary institutional ethics review, the
PROACH database was used to provide a pool of CAD
tients who were theoretically sampled (e.g., by age, sex,
ban/rural-living) (Morse, 1994). A screening question
as administered to each potential participant: ‘Have you
er heard of chelation therapy?’. Only those who
swered afﬁrmatively were considered for study parti-
ation. All qualitative interviews and surveys were
dertaken by telephone by trained research assistants
ter verbal informed consent was obtained.
. Stage A-decision-tree model building
Semi-structured audiotaped interviews were guided
nceptually by Kleinman’s (1980, 1992) work on health
ctors and the work by Quan et al. (2001, 2007) regarding
elation therapy use. The interviews were guided practi-
lly by Spradley’s (1979, 1980) work regarding ethno-
aphic methods. Kleinman (1980) identiﬁed three ‘health
ctors’ (professional, popular, and folk) from which people
 need of healthcare may seek and validate information.
e professional sector includes modern medicine, its
oviders, and its structures. The popular sector embraces
veral aspects including the individual-, family-, social-
d community-based beliefs and activities (e.g., choices/
cisions, roles, relationships, interactions, institutions)
980, 1992). The folk sector represents what Kleinman
992) called the ‘non-professional, non-bureaucratic’
actitioners who may or may not be afﬁliated with ‘sacred
aling’ or religious practices. Together, these sectors
present the potential breadth of context in which the
formants will experience and examine their healthcare.
Spradley (1980) used the descriptors of ‘grand tour’ and
ini tour’ when describing interview questions. As the
ords imply, ‘grand tour’ questions are general in nature
d aimed at helping the participant begin explain the big
cture or general ideas associated with the topic at hand.
ini tour’ questions are meant to help the participant
come more speciﬁc and begin to provide more detail. In
e ‘grand tour’ phases of exploration, questions began
ith the general ‘who, what, where, when, and how’ stems.
Thereafter, ‘mini tour’ questions focused on the same
dimensions as the ‘grand tour’ questions, however the
focus was on a smaller unit of experience. For example
questions such as ‘‘What are all the . . .?, Can you describe
in detail the . . .?, [and] Can you tell me more about all the
. . .?’’ (p.79) were used.
Interviews with 32 initial participants generally lasted
60–90 min per participant and were conducted at a time and
place agreeable to the informant. Audio-recorded inter-
views and ﬁeld notes were transcribed. Analysis of the data
began almost immediately as data were collected and were
undertaken using constant comparative methods (Polit and
Beck, 2003; Streubert and Carpenter, 1999). This immediate
analysis guided further theoretical sampling and data
gathering strategies. Members of the research team
inductively investigated the interview transcripts to create
a taxonomy of issues faced by people considering use of
chelation therapy, and to identify behavior contrasts/
differences as well as contextual constraints/conditions
surrounding the decisions. This was an iterative process,
that was stopped when data saturation was achieved, and
which culminated in a composite characterized by numer-
ous nodes or decision points and resulted in the key
outcomes (e.g., using or not using chelation therapy).
We needed to determine if the tree/model was logical and
complete by continually ‘walking through it’ and ‘testing’ it
against the qualitative data upon which it was based. Once
consensus was reached among the investigating team
members regarding each behavior contrast and its nature
(including choice alternatives, decision criteria and out-
comes), survey questions were developed assessing these
behaviors. These questions, which required a dichotomous
‘yes’ or ‘no’ response, became decision nodes and were
placed into a decision-tree model sequence. [Note: Though
called a decision-tree the major criterion of model devel-
opment is that it is hierarchical and does not necessarily look
exactly like a ‘tree’.] Once the model was completed, the
dichotomous questions posed at each decision point were
formatted into a structured questionnaire.
2.3. Stage B-decision-tree model preliminary testing and
reﬁnement
Using the structured questionnaire developed in Stage
A the decision-tree model was then (pilot) tested. The
structured questionnaire was administered to a new
sample of informants, as the decision-tree model had
already been ‘tested’ against the data provided by the
informants in Stage A. All interviews (n = 30) were under-
taken by telephone by trained research assistants.
This testing was undertaken to identify where the model
could fail or errors occur (e.g., when the model did not
explain the decision-maker’s choice, the questionnaire had
not been well formatted, the informant failed to understand
or respond to the questions in a manner that enabled them
to ‘proceed appropriately’ down the decision-tree path, or
interviewer error occurred (Gladwin, 1989)). Administra-
tion of the questionnaires was audio-recorded to enable
critique and validation of error identiﬁcation. Additional
‘ﬁeld notes’ were also taken and to enhance identiﬁcation of
any issues with administering the survey, or any model
fa
th
2
w
id
(c
th
w
te
s
d
T
a
a
s
e
u
S
m
n
T
T
K.M. King-Shier et al. / International Journal of Nursing Studies 49 (2012) 1074–1083 1077ilures (e.g., where the model did not adequately explain
e patients’ decision) or errors.
.4. Stage C-decision-tree model testing
This is the stage we wished to determine the degree to
hich the model could discriminate among/correctly
entify the people who fell within each outcome group
urrent user, previous user and never user of chelation
erapy). To do so, the reﬁned questionnaire (from Stage B)
as administered to informants (n = 167), over the
lephone by rigorously trained research assistants. A
hort questionnaire was also administered to obtain
emographic data to better characterize the study sample.
wenty interviews were randomly audio-tape recorded
nd ‘scored’ again by a second research assistant to enable
ssessment of interviewer inter-rater reliability.
The study sample was characterized using descriptive
tatistics (e.g., means, percentages). Then potential differ-
nces in demographics between current users, previous
sers and never users were examined using ANOVA or Chi-
quare, as appropriate. To examine the success rate of the
odel, Gladwin’s (1989) method was used; dividing the
umber of successes (correct path and outcomes) by the
number of cases (number of people surveyed). A model is
considered adequate if it was able to discriminate among/
correctly identify people who fell within each outcome
group at a rate of 85–90%. To examine the model in greater
detail, we compared the responses of current users,
previous users, and never users of chelation therapy for
each questionnaire item, using Chi-Square tests or Fisher
exact tests when there were low expected cell counts. The
goal of these comparisons was to identify potential key
junctures for these informants in coming to their decision
outcome. Data were analyzed using PASW Statistics 17.
3. Results
Globally, the taxonomy developed in Stage A among 32
CAD patients included: previous experience with or
learning about chelation therapy, openness to alternative
treatments, satisfaction with current level of (traditional)
care, physician opinion regarding chelation therapy, costs
associated with chelation therapy, perceived access to
chelation therapy provider, current state of health (good or
bad), and wanting to do ‘all one can’ for heart health (see
Table 1). The decision-making outcomes at this stage were
able 1
axonomy of factors that lead to using/not using chelation therapy.
Factors Exemplar comments
Previous experience with or
learning about chelation therapy
 I explored it on the internet and was satisﬁed with proceeding with using it.
 Just books and stuff, then a friend of mine was taking chelation from this particular doctor so I thought, well
it can’t hurt me.
 I was told that chelation therapy is the number one treatment in Europe and it fact they stated that in
Germany it is impossible to have heart surgery without ﬁrst going through a series of chelation therapy (CT)
treatments.
 I was somewhat familiar with chelation therapy being used for lead treatment, like for lead poisoning and I
was amazed when they started saying it was good for more than that. I wanted to know more and thought I
would give it a try.
 I met a man who looked in pretty rough shape and about three weeks later I met him again and he was
bouncing around and I asked him what happened to you- he said ‘‘I went to Mexico for this (CT) treatment’’
so I thought, well, if it can work for you then I guess it can help me.
Openness to alternative
treatments
 I try not to rely on drugs. . .I don’t feel that traditional healthcare is doing a good job.
 I’m very open to treatment as long as not drug related. I’m concerned about how quick doctors are to give a
drug. I’m all into the alternative stuff.
 I really don’t see any harm in alternative treatments, but I really would want to see how effective they are.
 I had tried about everything there was to try and it didn’t seem like anything worked, so I ﬁgured I would
give chelation therapy a try.
 I was not able to have the surgery (coronary artery bypass graft; CABG) because I had too many blockages, so
we heard about this chelation.
 I would only go with the proven treatment stuff.
 I saw chelation as no different than ﬂying to Mexico or China for some miracle cure. I was also concerned
about the infection factor.
Satisfaction with current traditional
care (including relationships)
 The whole essence of medicine is to treat the symptom, but not to treat the cause.
 I really don’t have much faith in the doctor. I don’t blame the medical profession, I just said ‘‘I want to go
home right now’’ and he discharged me.
 Every time I need a doctor, I can’t get him. My other doctor doesn’t really care about my signs and symptoms.
 Right now conventional medicine has got me ﬁxed so why go and try to break that?
 Well so far the traditional system seems to be working for me. I mean in the last year I’ve at least the
cardiologist told me that my, you know; my heart has improved in its function. It went from 31% to 41% so
that seemed to be, the medication seems to be doing its job.
Physician opinion regarding
chelation therapy
 The doctor has become much more interested in talking about it, he sees more and more people going to it so
he says it can’t be all bad either. He’s working closely with this chelation doctor.
 My doctor is for the chelation therapy treatments.
 The doctors didn’t tell me not to do it, they just weren’t happy with it because they were pushing their own
drugs.
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elation therapy.
The taxonomy was augmented to include other relevant
tails gleaned through the qualitative interviews and a
erarchical decision-tree model was developed. Initially
e model had 35 dichotomous questions. The tree ‘worked’
e., reﬂected the experience) for all of those 32 initial
rticipants.
Pilot testing of the survey questionnaire (Stage B) with 30
n-original informants, revealed that three of the questions
quired reﬁnement to enhance clarity of their meaning.
ewing the responses to the 35 questions, it was apparent
at some of the questions addressed the same phenomenon
d led to some informant confusion. Thus, the model was
o made more parsimonious (30 questions from 35
estions). As seen in Fig. 1, the ﬁnal model is as prescribed
 Gladwin (1989). The model is indeed hierarchical; is
aracterized by dichotomous questions that clearly reﬂect
e taxonomy developed in the previous stage and based on
e patient’s responses to the questions; and provides
portant contextual information of what led to their
cision outcome (to use or not use chelation therapy). The
odel was not put through another testing because the
estions and ﬂow were not changed substantially.
Finally, in Stage C, a sample of 167 current users
(n = 27), previous users (n = 72) and never users (n = 68) of
chelation therapy was recruited to test the decision-tree
model. Forty additional potential participants were
screened, but were excluded because they did not respond
afﬁrmatively to the screening question. The participants
had a mean age of 70 years (41–95 years). Thus it was not
surprising that most (115) identiﬁed that they were
retired, and of those who responded (152/167) approxi-
mately two thirds (68%) had a household income of less
than 60,000 ($CAN) per year (lower than the provincial
median income (Statistics Canada)). The majority of
participants (135/167; 81%) were married, and approxi-
mately 74% had a high school education or higher. Of those
who ever had chelation therapy to treat their heart disease
and reported the number of treatments (85/167), the mean
number of treatments was 59 (SD 64; range 1–300).
There were no differences between those who cur-
rently, previously, or never used chelation therapy with
regard to sex, having a high school education or higher, or
having previous MI or PCI (see Table 2). However, never-
users were signiﬁcantly younger than current or previous
chelation therapy users and had a signiﬁcantly shorter
period of time since diagnosis of heart disease. Also,
ble 1 (Continued )
actors Exemplar comments
 I haven’t discussed it with my GP/cardiologist, but I value their opinion so would listen to them about it and
weather I should do it or not.
 I didn’t tell [my GP] I was taking it! I wasn’t sure it was working but I felt a lot better.
 My doctor is an old-fashioned doctor, he understood but he did not like to be opposed.
 The doctor told me, ‘‘I’m not treating you if you’re going to continue (with chelation therapy)’’.
 The physician said no, it’s just a total waste of your money and there is no reason in the world to think it’s
going to work, don’t be stupid.
ost associated with
chelation therapy
 The only thing I object to is that fact that the government would not help at all with the cost of it.
 If I didn’t feel it was helping me, I wouldn’t be spending that kind of money, believe me!
 What’s holding me back is how much is its going to the cost!
 I don’t take the whole treatments because a whole course is 30 treatments and I can’t afford that.
 The conventional stuff did not work, so I said ok, my life is worth ﬁve thousand dollars, so I started doing
chelation therapy.
 The cost has not been a problem, but you know, what is your health worth?
 For how much I was spending, I didn’t feel the beneﬁts. It came down to a cost–beneﬁt analysis. I ended up
having CABG.
erceived access to chelation
therapy provider
 There was a clinic close by, but after it closed down, it would have meant a lot of driving that I couldn’t afford.
 There are not a lot of places to go, and it is an expensive proposition.
 I knew there was a physician in town doing chelation therapy, my wife used to go to him.
 A bunch of us rented bus, and we went there every two weeks for treatments.
 He is in town, so it’s easy.
 I do not like the provider in (city). He saw it as a ‘‘cash cow’’. It didn’t have a holistic feel, and he was in an
awful building. Now I have to go (out of province).
urrent state of health
(good or bad)
 I feel great, I have changed my diet and lost weight and the chelation therapy has been good.
 I feel good. Chelation therapy did not help me but I still believe in it.
 I have ongoing health issues.
 I feel good, I wanted to survive and it drives me to look at other modalities.
 I’ve felt great ever since the treatments.
 You’re not going to cut me open, unless it’s a last resort.
anting to do ‘all one
can’ for health
 I don’t want to be a burden to the family and have no quality of life – I don’t want that.
 The medical system in and of itself is just not enough.
 With all the medications and the chelation therapy I’m still alive; otherwise my heart would have given up.
 Those guys told me that they felt much better after CT but just because you feel good doesn’t mean you’re
healthier, I feel good after a vacation or a long sleep – but it doesn’t mean I’m healthier.
 It would be foolish to turn your back entirely on the medical community. Chelation therapy doesn’t do away
with the possibility of surgery, it’s a way of doing as much as possible for my heart health.
Fig. 1. Decision model for using/not using chelation therapy.
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rrent or never users to have had coronary artery bypass
aft (CABG) surgery.
The ability of the model to predict the appropriate
tcome was 93%. Though inter-rater reliability was
aintained at >95%, there were ten errors in the model
d two model failures. The ten errors were attributed to
vestigator error in correctly interpreting the response to
e question (e.g., taking the participant down a ‘yes’ path
ther than a ‘no’ path). Though the decision-making
tcomes (currently using chelation therapy or not
rrently using chelation therapy) were ultimately correct,
ese errors (had they not been identiﬁed) could have
rendered the contextual mechanisms by which the out-
come occurred as erroneous. The two model failures
occurred when participants moved down the path in such
a way that the question focused on the cost associated with
using chelation therapy (i.e., responded ‘yes’ to Q20 in
Fig. 1) was not asked; the patients’ decisions were not
adequately explained. In these cases, the participant
identiﬁed (and was recorded in ﬁeld notes) that high cost
was the major mechanism that prevented chelation use.
Finally, to identify potential key junctures in coming to
the decision outcome, current users, previous users, and
never users’ responses to each question were compared
relative to the outcome response (see Table 3). A
ble 2
mographic characteristics of 167 Stage C participants who were currently using, previously using, and had never used chelation therapy.
haracteristic Current (n = 27) Previous (n = 72) Never (n = 68) p
en (% (n)) 85.2% (23) 83.3% (60) 70.6% (48) x2 = 4.23; p = 0.121
ge (mean (SD)) 71.3 (9.6) 73.3 (8.2) 66.3 (9.3) F = 10.93, p < 0.001
 Highschool Education (% (n)) 74.1% (20) 70.8% (51) 76.5% (52) x2 = 5.18; p = 0.879
ime from Diagnosis (yrs; mean (SD)) 11.4 (10.9) 13.9 (8.6) 7.6 (7.6) F = 9.47; p < 0.001
revious MIa (% (n)) 51.9% (14) 44.4% (32) 64.7% (44) x2 = 5.83; p = 0.540
revious PCIb (% (n)) 51.9% (14) 44.4% (32) 64.7% (44) x2 = 2.89; p = 0.235
revious CABGc (% (n)) 22.2% (6) 48.6% (25) 29.4% (20) x2 = 8.4; p = 0.015
MI: myocardial infarction.
PCI: percutaneous coronary intervention.
CABG: coronary artery bypass graft surgery.
ble 3
tors signiﬁcantly related to the model outcomes.a
ree item and response User status p
Yes No
Current (n = 27) Previous (n = 72) Never (n = 68)
t the time of your CADb diagnosis, did you consider using non-traditional treatments? (Fig. 1; Q1)
Yes 55.6% (15/27) 34.7% (25/72) 19.1% (13/68) x2 = 12.37, p = 0.002
No 44.4% (12/27) 65.3% (47/72) 80.9% (55/68)
id you conclude that the possible beneﬁts of CTc outweighed any risk that may have been associated with its use? (Q8)
Yes 100% (27/27) 98.6% (69/70) 37.5% (15/40) x2 = 69.62, p < 0.001
No 0% (0/27) 1.4% (1/70) 62.5% (25/40)
ince your diagnosis has dissatisfaction with traditional health care options led you to consider other forms of treatment? (Q9)
Yes 58.3% (7/12) 27.6% (13/47) 10.5% (6/57) x2 = 14.28 p = 0.001
No 41.7% (5/12) 72.3% (34/47) 89.5% (51/57)
as the state of your health since your CAD diagnosis led you to consider non-traditional treatments? (Q10)
Yes 40.0% (2/5) 3.0% (1/33) 5.9% (3/51) p = 0.035b
No 60.0% (3/5) 97.0% (32/33) 94.1% (48/51)
o you view CT as a means of ‘doing all you can’ to help your heart health? (Q16)
Yes 100% (27/27) 97.0% (65/67) 56.7% (17/30) p = 0.04b
No 0% (0/27) 3.0% (2/67) 43.3% (13/30)
s your current physician a CT provider? (Q20)
Yes 26.9% (7/26) 12.7% (8/63) 0% (0/18) p = 0.029b
No 73.1% (19/26) 87.3% (55/63) 100% (18/18)
oes the cost of CT make it prohibitive for you? (Q21)
Yes 0% (0/20) 40.0% (24/60) 65.0% (13/20) x2 = 18.7, p < 0.001
No 100% (20/20) 60.0% (36/60) 35.0% (7/20)
id this (lack of access) completely dissuade you from CT use? (Q25)
Yes 0% (0/5) 64.3% (9/14) 100% (1/1) p = 0.033d
No 100% (5/5) 35.7% (5/14) 0% (0/1)
oes the current state of your health (and how you are feeling now) inﬂuence you toward CT use? (Q26)
Yes 100% (27/27) 14.3% (5/35) 50.0% (1/2) p < 0.001d
No 0% (0/27) 85.7% (30/35) 50.0% (1/2)
re you currently feeling so well that you feel you don’t need CT right now? (Q28)
Yes 0% (0/27) 100% (23/23) 100% (2/2) p < 0.001d
No 100% (27/27) 0% (0/23) 0% (0/2)
Note: Not all participants responded to each question in the model because they followed different paths along the decision tree.
CAD: coronary artery disease.CT: chelation therapy.
Fisher’s Exact Test (comparing current users and current non-users) used when expected cell count was less than 5.
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sed chelation therapy considered using non-traditional
eatments at the time of their CAD diagnosis. All of the
helation therapy users and the majority of the previous
sers agreed that the possible beneﬁts of chelation therapy
utweighed any risk that may be associated with its use as
ell as that using chelation therapy was a means of ‘doing
ll that could be done’ to help their heart health. A
igniﬁcantly greater proportion of never users of chelation
erapy did not respond afﬁrmatively to these items.
urrent users were more likely than the others to be
issatisﬁed with traditional healthcare options and
urrent and previous users were more likely than never
sers to have a physician who provides chelation therapy.
helation therapy users’ perceptions regarding their
urrent state of health led them unanimously toward its
se though it was not their state of health that led them to
onsider chelation therapy initially. Previous users’ current
ealth seemed to inﬂuence lack of chelation therapy use;
hich might be explained by their signiﬁcantly higher
ates of CABG surgery. The cost of chelation therapy, lack of
asy access, and feeling so well that using chelation
erapy was not needed were salient factors associated
ith lack of current use.
. Discussion and conclusion
.1. Discussion
How CAD patients come to the decision to use chelation
erapy, a yet unproven treatment modality (Anderson
t al., 2003; Ernst, 1997, 2000; Grier and Myers, 1993;
nudtson et al., 2002), is an important clinical issue. We
sed ethnographic decision-modeling to better understand
e contextual factors that may explain this phenomenon.
n important facet of using descriptive decision-modeling
 examine this clinical issue is that the junctures that lead
eople to different behavioral outcomes, can represent
laces at which education (i.e., for patients, healthcare
roviders), interventions (i.e., for patients, healthcare
roviders, or in the process of care), and health policy can
e better directed. The most important junctures in the
ecision-model for using or not using chelation therapy
ere: considering using non-traditional treatments; per-
eptions regarding potential risks and beneﬁts; cost; and
elieving that using chelation therapy was ‘doing all that
ey can’ to help their heart health.
Patients may consider using non-traditional treatments
r their heart disease, but the proportion of patients who do
o is unknown. Estimates suggest however, that nearly 30%
f Americans (Ni et al., 2002) use non-traditional treatments.
stin (1998) found that a holistic orientation to health was
ssociated with alternative therapy use in general. Studies
ave also revealed that non-traditional therapy use is
ssociated with high use of health care resources and
resence of chronic disease (Astin, 1998; Al-Windi, 2004).
hus, in the context of CAD patients, it is likely that a notable
roportion consider the use of non-traditional treatment.
ealthcare providers may have an important opportunity to
pact the decision-making process, especially when
AD patients are experiencing ongoing treatment or
deteriorating condition. Our results suggest that assistance
with ﬁnding appropriate (i.e., evidence-based) resources and
providing a non-judgmental environment would likely be
welcomed by CAD patients.
In keeping with the survey by Quan et al. (2007) nearly
19% (26/137) of study participants asked believed that risks
of using chelation therapy may outweigh the potential
beneﬁts. The Canadian Cardiovascular Society’s (1997)
statement regarding chelation therapy warns that its use
‘‘may cause renal tubular necrosis, arrhythmia, hypocalce-
mia, marrow depression, bleeding, hypotension or allergic
reaction’’. Yet, the majority of responding participants were
either unaware of these potential risks or were willing to
accept them based on their belief regarding beneﬁt. At this
juncture, healthcare providers have an important opportu-
nity to partner with CAD patients to, at minimum, monitor
their physiological response to chelation therapy, and to
support their continued use of evidence-based therapies.
The costs of chelation therapy can make its use
prohibitive for those who might otherwise wish to use it.
Forty percent of previous users and 65% of never users who
responded to a question regarding costs, indicated that the
cost of chelation therapy prohibited its use. The costs of
chelation therapy are not reimbursed by most health
insurance or supplementary medical insurance plans in
Canada. Knudtson et al. (2002) suggested that a typical 3-
month series of treatments costs $4000 (CAN), while others
suggest the treatment can be life-long and pose even more
signiﬁcant costs (Anderson et al., 2003; National Center for
Complementary and Alternative Medicine). Knudtson et al.
(2002) projected that Canadians spend approximately 17
million dollars per year on chelation therapy. It is unknown
how many more cardiovascular patients would use
chelation therapy if the cost was reduced or eliminated.
Costs of evidence-based therapies are not always fully-
insured and can pose a ﬁnancial burden on CAD patients. It
behooves healthcare providers to speak openly with CAD
patients about the ﬁnancial burdens of any medications and
to ensure that the prescribed medications are kept as
economical as possible. Until the results from the National
Institutes of Health (United States)-sponsored trial are
available, it is unlikely that insurance plans will adjust their
policy regarding coverage for chelation therapy.
The majority (88%; 109/124) of participants (users and
non-users) identiﬁed that using CT was a means of ‘doing all’
they could do to help their heart health. In a survey of 96
chelation therapy users, Quan et al. (2007) reported that
respondents wanted to ‘bring their health to the highest
possible level’ and ‘to seek every option possible’. Indeed,
most alternative therapies are used as an adjunct to
conventional therapy and not as a sole treatment modality
(Ni et al., 2002; Al-Windi, 2004; Montbriand, 1995b).
Despite the high cost, some CAD patients will use chelation
therapy to ‘do all they can’ to manage their disease. Again,
this is another point at which healthcare providers can work
with CAD patients to ensure that they are aware of the
expected effect of their evidence-based therapies, monitor
their physiological health while using chelation therapy, and
support their continued use of evidence-based therapies.
Finally, the majority of study participants were not
currently using chelation therapy (84%; 140/167). Yet, 59%
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evious chelation therapy users. All of the chelation
erapy current users and 25 of the non-users were asked
re you currently feeling so well that you feel you don’t
ed chelation therapy right now?’. The response to this
estion was signiﬁcantly associated with the outcome; all
 the chelation users responded ‘no’ and all of the
elation non-users responded ‘yes’. Indeed, a signiﬁcantly
eater proportion of previous users than others had
dergone CABG surgery. Quan et al. (2001, 2007) found
ter risk adjustment, current users of chelation therapy
ere less likely to have undergone percutaneous coronary
terventions or CABG surgery. This represents another
portunity for healthcare providers to assist CAD
tients. For example, discontinuing any medical therapy
r CAD without thorough consultation with the health-
re provider is potentially deleterious to their health.
rther, CAD patients’ fears or preferences may lead them
 use chelation therapy in lieu of proceeding with
rcutaneous coronary interventions or CABG surgery.
althcare providers ought to communicate that the CAD
tient who is using chelation therapy is able to access
ese recommended procedures at a future time.
There are strengths and limitations to this study. From a
ethodological perspective, ethnographic decision-model-
g is a powerful systematic mechanism by which phenom-
a such as ‘how’ and ‘why’ people make healthcare decisions
d shows great promise for use in other healthcare decision
enarios. The model developed for this study had a capacity
 predict the appropriate outcome 93% of the time. Gladwin
989) suggests that a model should have greater than 85%
edictive accuracy, but not 100% accuracy, as it would likely
o broad and not reﬂect the key elements of the decision. A
itation of this work was that there were two model
lures. It is possible that reordering the questions would
medy this problem. In addition, a possible limitation of this
ork is that the model would be characterized and
monstrate success differently (e.g., hierarchical order of
estions) had larger samples been used in Stages A or B.
us, further external validation is warranted.
. Conclusions
The results of this study provide important contextual
formation for patients, providers and policy-makers
garding the factors that inﬂuence people to make decisions
garding the use (or not) of chelation therapy. Chelation
erapy is an unproven therapy for improving the symptoms
 CAD. Until more deﬁnitive evidence is available, patient
ould gain from increased education regarding the risks and
neﬁts of using non-traditional treatments such as CT alone
 as an adjunct to traditional therapies. Healthcare providers
o need to be aware of and try to mitigate their role in the
asons why CAD patients opt for unproven therapies such as
. Finally, policy makers may need to consider the ﬁnancial
neﬁts gleaned by CT providers as well as the ﬁnancial
rden of using CT on patients.
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